JP6346622B2 - ナトリウムチャネルの調節剤としてのアミド - Google Patents
ナトリウムチャネルの調節剤としてのアミド Download PDFInfo
- Publication number
- JP6346622B2 JP6346622B2 JP2015556113A JP2015556113A JP6346622B2 JP 6346622 B2 JP6346622 B2 JP 6346622B2 JP 2015556113 A JP2015556113 A JP 2015556113A JP 2015556113 A JP2015556113 A JP 2015556113A JP 6346622 B2 JP6346622 B2 JP 6346622B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- another embodiment
- benzamido
- pain
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*(C)(C(c(c(*)cc(C1=*C1)c1)c1Oc1ccc(*)cc1)=O)C(C=C1)=CC(CC2C(*)=C2)*=C1C(OC)=* Chemical compound C*(C)(C(c(c(*)cc(C1=*C1)c1)c1Oc1ccc(*)cc1)=O)C(C=C1)=CC(CC2C(*)=C2)*=C1C(OC)=* 0.000 description 5
- DTKQCLRHNWDXBG-UHFFFAOYSA-N C=Nc(ccc(F)c1)c1Cl Chemical compound C=Nc(ccc(F)c1)c1Cl DTKQCLRHNWDXBG-UHFFFAOYSA-N 0.000 description 1
- LXWFHMREWLOKLM-UHFFFAOYSA-N CC(C)CCOc(cc1)ccc1N Chemical compound CC(C)CCOc(cc1)ccc1N LXWFHMREWLOKLM-UHFFFAOYSA-N 0.000 description 1
- MDYXLRQCQPAWEX-UHFFFAOYSA-N CN(C)c(ccc(F)c1)c1F Chemical compound CN(C)c(ccc(F)c1)c1F MDYXLRQCQPAWEX-UHFFFAOYSA-N 0.000 description 1
- HKWSUHGMFVMEIM-UHFFFAOYSA-N COc(cc1)cc(Cl)c1Oc(ccc(C(F)(F)F)c1)c1C(Nc1ccc(C(O)=O)nc1)=O Chemical compound COc(cc1)cc(Cl)c1Oc(ccc(C(F)(F)F)c1)c1C(Nc1ccc(C(O)=O)nc1)=O HKWSUHGMFVMEIM-UHFFFAOYSA-N 0.000 description 1
- VQNBFIKXEZCCAT-UHFFFAOYSA-N COc(cc1)cc(OC)c1N=C Chemical compound COc(cc1)cc(OC)c1N=C VQNBFIKXEZCCAT-UHFFFAOYSA-N 0.000 description 1
- SYSZENVIJHPFNL-UHFFFAOYSA-N COc(cc1)ccc1I Chemical compound COc(cc1)ccc1I SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 1
- CXNVOWPRHWWCQR-UHFFFAOYSA-N Cc(cc(cc1)Cl)c1N Chemical compound Cc(cc(cc1)Cl)c1N CXNVOWPRHWWCQR-UHFFFAOYSA-N 0.000 description 1
- JWQUBAUGVPTBAE-UHFFFAOYSA-N Cc(cc(cc1)F)c1NC Chemical compound Cc(cc(cc1)F)c1NC JWQUBAUGVPTBAE-UHFFFAOYSA-N 0.000 description 1
- MIRMWZQQRUXCNH-UHFFFAOYSA-N Cc(cc(cc1)F)c1Oc(cc(c(Cl)c1)Cl)c1C(Nc1ccc(C(O)=O)nc1)=O Chemical compound Cc(cc(cc1)F)c1Oc(cc(c(Cl)c1)Cl)c1C(Nc1ccc(C(O)=O)nc1)=O MIRMWZQQRUXCNH-UHFFFAOYSA-N 0.000 description 1
- ZWSJDCCDISWMKX-UHFFFAOYSA-N Cc(cc(cc1)F)c1Oc1ccc(C(F)(F)F)cc1C(Nc(cc1)ccc1C(O)=O)=O Chemical compound Cc(cc(cc1)F)c1Oc1ccc(C(F)(F)F)cc1C(Nc(cc1)ccc1C(O)=O)=O ZWSJDCCDISWMKX-UHFFFAOYSA-N 0.000 description 1
- AKOGFIZZLZJNQH-UHFFFAOYSA-N Cc(cc(cc1)F)c1Oc1ccc(C(F)(F)F)cc1C(Nc1ccc(C(O)=O)nc1)=O Chemical compound Cc(cc(cc1)F)c1Oc1ccc(C(F)(F)F)cc1C(Nc1ccc(C(O)=O)nc1)=O AKOGFIZZLZJNQH-UHFFFAOYSA-N 0.000 description 1
- CXTIUQIZWCABPV-UHFFFAOYSA-N Cc(ccc(F)c1)c1OC Chemical compound Cc(ccc(F)c1)c1OC CXTIUQIZWCABPV-UHFFFAOYSA-N 0.000 description 1
- RRSGOCVSLFHGAX-UHFFFAOYSA-N Cc1cc(Cl)ccc1Oc1ccc(C(F)(F)F)cc1C(Nc1ccc(C(O)=O)nc1)=O Chemical compound Cc1cc(Cl)ccc1Oc1ccc(C(F)(F)F)cc1C(Nc1ccc(C(O)=O)nc1)=O RRSGOCVSLFHGAX-UHFFFAOYSA-N 0.000 description 1
- RTUDBROGOZBBIC-UHFFFAOYSA-N FC(Oc(cc1)ccc1I)(F)F Chemical compound FC(Oc(cc1)ccc1I)(F)F RTUDBROGOZBBIC-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N Nc(cc1)ccc1F Chemical compound Nc(cc1)ccc1F KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- TWHKITDGPNXHCU-UHFFFAOYSA-N OC(c(cc1)ccc1NC(c(cc(c(Cl)c1)Cl)c1Oc(cccc1)c1OC(F)F)=O)=O Chemical compound OC(c(cc1)ccc1NC(c(cc(c(Cl)c1)Cl)c1Oc(cccc1)c1OC(F)F)=O)=O TWHKITDGPNXHCU-UHFFFAOYSA-N 0.000 description 1
- YNBSBKHHRRBEHX-UHFFFAOYSA-N OC(c(nc1)ccc1NC(c(c(C(F)(F)F)cc(C(F)(F)F)c1)c1Oc(cc1)ccc1F)=O)=O Chemical compound OC(c(nc1)ccc1NC(c(c(C(F)(F)F)cc(C(F)(F)F)c1)c1Oc(cc1)ccc1F)=O)=O YNBSBKHHRRBEHX-UHFFFAOYSA-N 0.000 description 1
- IUYUKZBMJINCLE-UHFFFAOYSA-N OC(c(nc1)ccc1NC(c(ccc(C(F)(F)F)c1)c1Oc(cc1)ccc1F)=O)=O Chemical compound OC(c(nc1)ccc1NC(c(ccc(C(F)(F)F)c1)c1Oc(cc1)ccc1F)=O)=O IUYUKZBMJINCLE-UHFFFAOYSA-N 0.000 description 1
- ZJDFLPLEPVWDIP-UHFFFAOYSA-N OC(c(nc1)ccc1NC(c1cc(C(F)(F)F)ccc1Oc(ccc(F)c1)c1Cl)=O)=O Chemical compound OC(c(nc1)ccc1NC(c1cc(C(F)(F)F)ccc1Oc(ccc(F)c1)c1Cl)=O)=O ZJDFLPLEPVWDIP-UHFFFAOYSA-N 0.000 description 1
- QAJFPIFCJNLXPC-UHFFFAOYSA-N OC(c(nc1)ccc1NC(c1cc(C(F)(F)F)ccc1Oc1ccccc1)=O)=O Chemical compound OC(c(nc1)ccc1NC(c1cc(C(F)(F)F)ccc1Oc1ccccc1)=O)=O QAJFPIFCJNLXPC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759062P | 2013-01-31 | 2013-01-31 | |
| US61/759,062 | 2013-01-31 | ||
| PCT/US2014/013667 WO2014120820A1 (en) | 2013-01-31 | 2014-01-29 | Amides as modulators of sodium channels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016508500A JP2016508500A (ja) | 2016-03-22 |
| JP2016508500A5 JP2016508500A5 (enExample) | 2017-03-09 |
| JP6346622B2 true JP6346622B2 (ja) | 2018-06-20 |
Family
ID=50114569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556113A Active JP6346622B2 (ja) | 2013-01-31 | 2014-01-29 | ナトリウムチャネルの調節剤としてのアミド |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9108903B2 (enExample) |
| EP (1) | EP2951155B1 (enExample) |
| JP (1) | JP6346622B2 (enExample) |
| KR (1) | KR102226588B1 (enExample) |
| CN (1) | CN104968647B (enExample) |
| AR (1) | AR094668A1 (enExample) |
| AU (1) | AU2014212431B2 (enExample) |
| BR (1) | BR112015018284B1 (enExample) |
| CA (1) | CA2898653C (enExample) |
| IL (1) | IL240196B (enExample) |
| MX (1) | MX359882B (enExample) |
| RU (1) | RU2658920C2 (enExample) |
| SG (1) | SG11201505954RA (enExample) |
| TW (1) | TWI659945B (enExample) |
| WO (1) | WO2014120820A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2857687T3 (es) | 2013-01-31 | 2021-09-29 | Vertex Pharma | Piridona amidas como moduladores de los canales de sodio |
| CN105073738B (zh) | 2013-01-31 | 2018-01-05 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的喹啉及喹喔啉酰胺类 |
| PE20160548A1 (es) | 2013-07-19 | 2016-05-21 | Vertex Pharma | Sulfonamidas como moduladores de canales de sodio |
| CA2931550C (en) | 2013-12-13 | 2023-09-26 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| EP3625214B1 (en) | 2017-05-16 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| CA3069720A1 (en) * | 2017-07-11 | 2019-01-17 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2019157505A1 (en) | 2018-02-12 | 2019-08-15 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
| US12344595B2 (en) | 2018-11-02 | 2025-07-01 | Merck Sharp & Dohme Llc | 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors |
| KR102860523B1 (ko) | 2018-11-02 | 2025-09-16 | 머크 샤프 앤드 돔 엘엘씨 | Nav1.8 억제제로서의 2-아미노-n-헤테로아릴-니코틴아미드 |
| BR112021012909A2 (pt) * | 2019-01-04 | 2021-09-14 | Jiangsu Hengrui Medicine Co., Ltd. | Derivado de 6-oxo-1,6-di-hidropiridazina, método de preparação do mesmo e uso médico do mesmo |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| CN112996776B (zh) * | 2019-02-20 | 2024-03-15 | 福建盛迪医药有限公司 | 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用 |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| TWI770607B (zh) * | 2019-09-12 | 2022-07-11 | 大陸商上海濟煜醫藥科技有限公司 | 吡啶氮氧化合物及其製備方法和用途 |
| MX2022006865A (es) | 2019-12-06 | 2022-07-11 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio. |
| CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
| EP4167994A4 (en) | 2020-06-17 | 2024-07-24 | Merck Sharp & Dohme LLC | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDE AS NAV1.8 INHIBITORS |
| JP7323723B2 (ja) | 2020-06-17 | 2023-08-08 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド |
| CN113880771B (zh) * | 2020-07-03 | 2023-09-19 | 福建盛迪医药有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
| CN114031518B (zh) * | 2020-12-08 | 2023-08-18 | 成都海博为药业有限公司 | 一种苄胺或苄醇衍生物及其用途 |
| CN112225695B (zh) * | 2020-12-15 | 2021-03-02 | 上海济煜医药科技有限公司 | 一种氮氧化合物及其制备方法和用途 |
| JP2024509939A (ja) * | 2021-03-11 | 2024-03-05 | シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド | ピリジン窒素酸化物の結晶形態およびその使用 |
| MX2023013146A (es) | 2021-05-07 | 2023-11-28 | Merck Sharp & Dohme Llc | Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8. |
| AU2022283934A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| CN117794920A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂 |
| AU2022286511A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| KR20240031299A (ko) | 2021-06-04 | 2024-03-07 | 버텍스 파마슈티칼스 인코포레이티드 | (2r,3s,4s,5r)-4-[[3-(3,4-디플루오로-2-메톡시-페닐)-4,5-디메틸-5-(트리플루오로메틸)테트라하이드로푸란-2-카르보닐]아미노]피리딘-2-카르복사미드를 포함하는 고체 투여 형태 및 투여 요법 |
| CA3221938A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| JP2024520646A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド類似体 |
| CN119487003A (zh) | 2022-04-22 | 2025-02-18 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的杂芳基化合物 |
| AU2023255771A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| JP2025513454A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| JP2025513455A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| GEAP202516637A (en) | 2022-04-25 | 2025-03-25 | Siteone Therapeutics Inc | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
| WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| TW202434235A (zh) * | 2023-01-18 | 2024-09-01 | 芬蘭商奧利安公司 | ３－（４，５－二氯－２－（４－（三氟甲氧基）苯氧基）苯甲醯胺基）吡啶１－氧化物的製備方法 |
| AU2024367861A1 (en) | 2023-10-23 | 2026-05-07 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| AU2024365648A1 (en) | 2023-10-23 | 2026-04-30 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| WO2025160286A1 (en) | 2024-01-24 | 2025-07-31 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
| TW202606663A (zh) | 2024-06-28 | 2026-02-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2511231A (en) | 1949-03-26 | 1950-06-13 | Eastman Kodak Co | 1-cyanophenyl-3-acylamino-5-pyrazolone couplers for color photography |
| MX2008013194A (es) | 2006-04-11 | 2008-12-01 | Vertex Pharma | Composiciones utiles como inhibidores de canales de sodio regulados por voltaje. |
| MX2010003864A (es) | 2007-10-11 | 2010-06-01 | Vertex Pharma | Amidas utiles como inhibidores de canales de sodio dependientes de voltaje. |
| AU2008310663A1 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
| JP5555169B2 (ja) | 2007-10-11 | 2014-07-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド |
| CN105254557A (zh) * | 2009-05-29 | 2016-01-20 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
-
2014
- 2014-01-29 AR ARP140100282A patent/AR094668A1/es unknown
- 2014-01-29 MX MX2015009591A patent/MX359882B/es active IP Right Grant
- 2014-01-29 WO PCT/US2014/013667 patent/WO2014120820A1/en not_active Ceased
- 2014-01-29 RU RU2015136779A patent/RU2658920C2/ru active
- 2014-01-29 SG SG11201505954RA patent/SG11201505954RA/en unknown
- 2014-01-29 US US14/167,741 patent/US9108903B2/en active Active
- 2014-01-29 AU AU2014212431A patent/AU2014212431B2/en active Active
- 2014-01-29 CN CN201480006878.4A patent/CN104968647B/zh active Active
- 2014-01-29 CA CA2898653A patent/CA2898653C/en active Active
- 2014-01-29 BR BR112015018284-4A patent/BR112015018284B1/pt not_active IP Right Cessation
- 2014-01-29 EP EP14704981.1A patent/EP2951155B1/en active Active
- 2014-01-29 JP JP2015556113A patent/JP6346622B2/ja active Active
- 2014-01-29 TW TW103103690A patent/TWI659945B/zh not_active IP Right Cessation
- 2014-01-29 KR KR1020157023600A patent/KR102226588B1/ko not_active Expired - Fee Related
-
2015
- 2015-07-27 US US14/809,841 patent/US9421196B2/en active Active
- 2015-07-28 IL IL240196A patent/IL240196B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| NZ710293A (en) | 2020-09-25 |
| MX2015009591A (es) | 2016-04-15 |
| HK1217692A1 (en) | 2017-01-20 |
| AU2014212431A1 (en) | 2015-08-06 |
| JP2016508500A (ja) | 2016-03-22 |
| KR102226588B1 (ko) | 2021-03-11 |
| EP2951155B1 (en) | 2019-06-19 |
| WO2014120820A9 (en) | 2015-07-02 |
| TWI659945B (zh) | 2019-05-21 |
| MX359882B (es) | 2018-10-15 |
| KR20150118964A (ko) | 2015-10-23 |
| SG11201505954RA (en) | 2015-08-28 |
| CA2898653C (en) | 2021-09-28 |
| US9421196B2 (en) | 2016-08-23 |
| US20150328196A1 (en) | 2015-11-19 |
| CN104968647B (zh) | 2018-01-26 |
| EP2951155A1 (en) | 2015-12-09 |
| RU2015136779A (ru) | 2017-03-07 |
| US9108903B2 (en) | 2015-08-18 |
| AR094668A1 (es) | 2015-08-19 |
| BR112015018284A2 (pt) | 2017-07-18 |
| US20140221435A1 (en) | 2014-08-07 |
| CA2898653A1 (en) | 2014-08-07 |
| CN104968647A (zh) | 2015-10-07 |
| WO2014120820A1 (en) | 2014-08-07 |
| IL240196B (en) | 2019-08-29 |
| IL240196A0 (en) | 2015-09-24 |
| TW201443005A (zh) | 2014-11-16 |
| BR112015018284B1 (pt) | 2023-03-07 |
| RU2658920C2 (ru) | 2018-06-26 |
| AU2014212431B2 (en) | 2018-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6362623B2 (ja) | ナトリウムチャネルの調節剤としてのキノリンおよびキノキサリンアミド | |
| JP6389194B2 (ja) | ナトリウムチャネルの調節剤としてのピリドンアミド | |
| JP6337109B2 (ja) | ナトリウムチャネルの調節剤としてのスルホンアミド | |
| US9421196B2 (en) | Amides as modulators of sodium channels | |
| JP6463580B2 (ja) | ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ | |
| HK1217692B (en) | Amides as modulators of sodium channels | |
| HK1217691B (en) | Quinoline and quinazoline amides as modulators of sodium channels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170130 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170130 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171109 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180316 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180501 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180525 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6346622 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |